Clinical Trial Search

Primary: Empowerment Via the Personal Progress Scale Revised — 129.82; 132.25; 146.13; 137.24 score on a scale — p=<.05

Primary: Number of Patients With Cycle 1 and 2 Dose Limiting Toxicities Attributable to Nanoparticle Albumin-bound Rapamycin — 1; 2; 1; 1 Participants

Primary: Number of Participants Returning to Care Following Discharge From the Emergency Department — 14; 12 Participants

Primary: Employment as Measured in Outcome Questionnaire — 11; 23; 14; 24 Participants — p=.15

Primary: Mean 24-Hour Systolic Ambulatory Blood Pressure Values — 122.8; 123.0 mmHg

Primary: Change in Pain Intensity — 5; 4.5; 4.5; 1 units on a scale

Primary: Number of Participants With Imagio Image Sets Collected — 38 Participants

Primary: Effect of Tenapanor to Achieve Target s-P Levels of Less Than or Equal to 5.5 mg/dL — 52; 58; 19 Participants

Primary: Achieving Normal Serum Phosphorus Level — 36; 21 Participants — p=0.7439

Primary: Number of Participants With Retained Hemothorax Following Initial Chest Tube Placement Requiring Intervention — 51; 48 Number of Participants — p=0.036

Primary: Apnea-Hypopnea Index (AHI) — 24.4 times per hour

Primary: Rate of Patient Recruitment to a Randomised Chemoprevention Study in Men Enrolled on an Active Surveillance Programme for Prostate Cancer. Number Accrued Per Month…

Primary: Absolute Change in Mean Lesion Counts at Week 12 — -18.5; -13.3; -26.3; -18.7 lesion counts

Primary: Number of Participants With Hospital Admissions, Emergency Department Visits, Urgent Clinic Visits, and Death — 0; 3 Participants

Primary: Change From Baseline (CFB) to the End of 12-Week Treatment Period in Mean Number of Micturition/24 Hours in Mirabegron 50 mg Group — -3.76 micturitions per 24 hours…